

Cell-specific perforation using functionalized plasmonic nanoparticles and near-infrared femtosecond laser

Eric Bergeron^{1*}, Christos Boutopoulos^{1, 2}, Rosalie Martel^{1*}, Alexandre Torres^{1*}, Camille Rodriguez^{1*}, Jukka Niskanen^{3*}, Jean-Jacques Lebrun^{4*}, Françoise M. Winnik^{3, 5*}, Przemyslaw Sapieha^{6*} and Michel Meunier^{1*}

¹ Polytechnique Montréal, Department of Engineering Physics, Canada

² University of St. Andrews, SUPA, School of Physics and Astronomy, United Kingdom

³ Université de Montréal, Faculty of Pharmacy and Department of Chemistry, Canada

⁴ McGill University Health Centre, Division of Medical Oncology, Department of Medicine, Canada

⁵ Nanoarchitectonics (MANA) and National Institute for Materials Science (NIMS), World Premier International (WPI) Research Center Initiative, International Center for Materials, Japan

⁶ Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Department of Ophthalmology, Canada

Introduction: Gold nanoparticles (AuNPs) have found numerous applications in nanomedicine, in view of their robustness, ease of functionalization and low toxicity^{[1],[2]}. Our group has demonstrated that near-infrared (NIR) femtosecond (fs) laser excitation of 100 nm citrate-capped AuNPs enables high cell membrane perforation, while maintaining high cell viability and enabling transfection of DNA plasmids into cancer cells^[3]. Such laser irradiation of AuNPs minimizes the heat absorption from AuNPs and biological tissues since they absorb energy very weakly in the NIR range^{[4],[5]}. The amplification of the electromagnetic field around the irradiated AuNP can cause the generation of nanoplasma leading to a nanobubble, thus inducing cell perforation without AuNP fragmentation^{[3],[6]-[8]}.

Since selective targeting of diseased cells can increase therapeutic efficacy and limit off-target adverse effects, the next step for selective cell optoporation is to develop stable AuNPs which labeled targeted cells without affecting surrounding non-targeted cells. Here the receptor CD44 strongly expressed by cancer cells was used as a model for selective targeting and optoporation.

Materials: Monoclonal anti-CD44 antibodies (Abs) from abcam. Orthopyridyl-disulfide-poly(ethylene glycol) (5kDa)-*N*-hydroxysuccinimide (OPSS-PEG-NHS) and HS-PEG (5kDa) from Nanocs. Citrate-capped AuNPs (50 µg/mL, 100 nm in diameter) from Nanopartz. HS-PEG (2kDa), PBS, Lucifer Yellow (LY) and DAPI from Sigma-Aldrich. Tetramethylrhodamine-wheat germ agglutinin (WGA) and Alexa 488-Abs from Life Technologies.

Methods: Abs were conjugated to OPSS-PEG-NHS (OPSS-PEG-Ab). AuNPs were functionalized with 0.01 OPSS-PEG-Ab/nm² and 5 µM HS-PEG^[9]. The stability of functionalized AuNPs (fAuNPs) was evaluated by UV-visible spectroscopy and zeta potential measurements. Cells were incubated for 3 h with 8 µg/mL fAuNPs, washed with PBS, incubated with LY and treated with a 45 fs laser at 800 nm (Spitfire, Spectra Physics). Two hours after the laser treatment, the cells were washed with PBS, fixed and stained with DAPI.

Results and Discussion: The fAuNPs with HS-PEG (5kDa) were colloidally stable in cell culture medium containing serum proteins, while fAuNPs with HS-PEG (2kDa) were unstable.

Selective targeting with stable fAuNPs was confirmed by immunofluorescence, darkfield and fluorescence imaging, flow cytometry and SEM on targeted CD44⁺ human cells (MDA-MB-231 breast cancer and ARPE-19 retinal pigmented epithelium) and on non-targeted CD44⁻ mouse 661W photoreceptors (Fig. 1). The fAuNPs attached mostly as single particles 115 times more to targeted cells than to non-targeted cells.




Fig. 1. Selective labeling of targeted cells incubated with stable fAuNPs.
(A-C) Immunofluorescence of CD44 receptors in CD44⁺ MDA-MB-231, CD44⁺ ARPE-19 and CD44⁻ 661W cells. Darkfield (D-F) and fluorescence (G-I) imaging of cells with fAuNPs. Anti-CD44 Abs were detected with Alexa Fluor 488 conjugated to goat anti-rat IgG Abs and cell nuclei were stained with DAPI (A-C, G-I). (J-L) Mean forward scattering intensity of cells with fAuNPs was recorded by flow cytometry and normalized to cells without fAuNPs for each cell type (CTL). Results are expressed as means $\pm$ standard deviation. Statistically significant differences are indicated by *** p < 0.001 in comparison to CTL. (M-O) Scanning electron microscopy (SEM) of cells with fAuNPs.

Selective optoporation of targeted cells was demonstrated with stable fAuNPs enhancing fs laser without affecting surrounding non-targeted cells (Fig. 2 and 3). Perforated cells in the laser-irradiated area were mainly targeted cells which accumulated LY, while untreated cells remained non-perforated^[10].




Fig. 2. Selective optoporation of targeted cells without affecting surrounding non-targeted cells.
Fluorescence imaging of targeted CD44⁺ MDA-MB-231 (A,B) and CD44⁺ ARPE-19 (C,D) cells in co-culture with CD44⁻ 661W cells stained with WGA incubated with stable fAuNPs. LY was added before laser treatment (60 mJ/cm², 500 Hz) and cell nuclei were stained with DAPI. The laser irradiated area is shown in the left box delimited with dashed line. The magnified central area from (A) and (C) are shown in (B) and (D), respectively.




Fig. 3. Schematic representation of selective optoporation with fs laser and stable fAuNPs.

Conclusion: The proposed novel highly versatile treatment paradigm can be adapted to target and perforate other cell populations by adapting to desired biomarkers. Since living biological tissues absorb energy very weakly in the NIR range, the developed non-invasive tool may provide a safe, cost-effective clinically relevant approach to ablate pathologically deregulated cells and limit complications associated with surgical interventions.

This work was supported by Le Fonds de recherche du Québec, Consortium québécois sur la découverte du médicament (CQDM), the Natural Science and Engineering Research Council of Canada (NSERC) and Canadian Institutes of Health Research (CIHR). EB received funding from Fonds de recherche du Québec – Santé and CB acknowledges funding from the EU under a Marie Curie Fellowship, FP7-PEOPLE-2013-IOF, project reference 624888. David Rioux, Sergiy Patskovsky, Rémi Lachaine, Alexandra Thibeault-Eybalin, Ariel Wilson, Flavie Lavoie-Cardinal and Yves Drolet are acknowledged for technical assistance and fruitful discussions. The authors also thank Danièle Gagné and Gaël Dulude from the IRIC flow cytometry platform for assistance with flow cytometry.

References:

- [1] X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed (2007) Gold nanoparticles: Interesting optical properties and recent applications in cancer diagnostics and therapy, *Nanomedicine* 2(5):681–693.
- [2] K. Weintraub (2013) The new gold standard, *Nature* 495(7440):S14–S16.
- [3] J. Baumgart, L. Humbert, É. Boulais, R. Lachaine, J.-J. Lebrun and M. Meunier (2012) Off-resonance plasmonic enhanced femtosecond laser optoporation and transfection of cancer cells, *Biomaterials* 33(7):2345–2350.
- [4] É. Boulais, R. Lachaine and M. Meunier (2012) Plasma mediated off-resonance plasmonic enhanced ultrafast laser-induced nanocavitation, *Nano Letters* 12(9):4763–4769.
- [5] R. Weissleder (2001) A clearer vision for in vivo imaging, *Nature Biotechnology* 19(4):316–317.
- [6] E. Boulais, R. Lachaine, A. Hatf and M. Meunier (2013) Plasmonics for pulsed-laser cell nanosurgery: Fundamentals and applications, *Journal of Photochemistry and Photobiology C: Photochemistry Reviews* 17:26–49.
- [7] C. Boutopoulos, E. Bergeron and M. Meunier (2015) Cell perforation mediated by plasmonic bubbles generated by a single near infrared femtosecond laser pulse, *Journal of Biophotonics*, in press. doi: 10.1002/jbio.201500135.

- [8] W. Ding, E. Bergeron, R. Lachaine and M. Meunier, (2015) Nanomaterial-assisted light-induced poration and transfection of mammalian cells (chapter 16) IN: Applications of Nanoscience in Photomedicine, Editors: M. R. Hamblin and P. Avci, Sawston (Cambridge, United Kingdom): Woodhead Publishing Limited, pp. 331–376. doi: 10.1533/9781908818782.331, ISBN: 1907568670.
- [9] S. Patskovsky, E. Bergeron, D. Rioux and M. Meunier (2015) Wide-field hyperspectral 3D imaging of functionalized gold nanoparticles targeting cancer cells by reflected light microscopy, *Journal of Biophotonics* 8(5):401–407.
- [10] E. Bergeron, C. Boutopoulos, R. Martel, A. Torres, C. Rodriguez, J. Niskanen, J.-J. Lebrun, F. M. Winnik, P. Sapieha and M. Meunier (2015) Cell-specific optoporation with near-infrared ultrafast laser and functionalized gold nanoparticles, *Nanoscale* (in revision).

Keywords: nanoparticle, biofunctionalization, theranostic, targeting delivery **Conference:** 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016.

Presentation Type: New Frontier Oral **Topic:** Cell-targeting biomaterials in theranostic delivery

Citation: Bergeron E, Boutopoulos C, Martel R, Torres A, Rodriguez C, Niskanen J, Lebrun J, Winnik FM, Sapieha P and Meunier M (2016). Cell-specific perforation using functionalized plasmonic nanoparticles and near-infrared femtosecond laser. *Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress*. doi: 10.3389/conf.FBIOE.2016.01.02117

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (<https://creativecommons.org/licenses/by/4.0/>) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers' terms and conditions please see <https://www.frontiersin.org/legal/terms-and-conditions>. Received: 27 Mar 2016; Published Online: 30 Mar 2016.

*** Correspondence:**

Dr. Eric Bergeron, Polytechnique Montréal, Department of Engineering Physics, Montréal, QC, Canada, Email1

Dr. Rosalie Martel, Polytechnique Montréal, Department of Engineering Physics, Montréal, QC, Canada, rosalie.martel@polymtl.ca

Dr. Alexandre Torres, Polytechnique Montréal, Department of Engineering Physics, Montréal, QC, Canada, alto2105@gmail.com

Dr. Camille Rodriguez, Polytechnique Montréal, Department of Engineering Physics, Montréal, QC, Canada, camille.rodriguez@polymtl.ca

Dr. Jukka Niskanen, Université de Montréal, Faculty of Pharmacy and Department of Chemistry, Montréal, QC, Canada, jukka.niskanen@helsinki.fi

Dr. Jean-Jacques Lebrun, McGill University Health Centre, Division of Medical Oncology, Department of Medicine, Montréal, QC, Canada, jj.lebrun@mcgill.ca

Dr. Françoise M Winnik, Université de Montréal, Faculty of Pharmacy and Department of Chemistry, Montréal, QC, Canada, francoise.winnik@umontreal.ca

Dr. Przemyslaw Sapieha, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Department of Ophthalmology, Montréal, QC, Canada, mike.sapieha@umontreal.ca

Dr. Michel Meunier, Polytechnique Montréal, Department of Engineering Physics, Montréal, QC, Canada, michel.meunier@polymtl.ca